Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Ozanimod Intervention Study (COZI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04405102
Recruitment Status : Terminated (Screening was stopped by the Sponsor (43/48 participants enrolled), given the very low number of eligible patients (high vaccination rate and occurrence of the Omicron variant). The last patient randomized performed his follow-up visit.)
First Posted : May 28, 2020
Last Update Posted : May 20, 2022
Sponsor:
Collaborators:
Celgene
Bristol-Myers Squibb
Information provided by (Responsible Party):
François Lellouche, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

Brief Summary:

The virus SARS-CoV-2 causes severe pneumonia which, in a proportion of patients progresses towards an Acute Respiratory Distress Syndrome (ARDS) mainly related to the antiviral immune response. To date, there is no available treatment that significantly improves outcome of patients with COVID-19 pneumonia. Sphingosine-1-phosphate receptor 1 (S1P1) ligands control vascular leakage in the airways and sphingosine-1-phosphate (S1P) receptor ligands devoid of activity on sphingosine-1-phosphate receptor 3 (S1P3) show an excellent safety profile, including ozanimod. Critically, S1P1 ligands mildly impact, but do not compromise viral clearance and they reduced lung injury in preclinical models, even without concomitant use of antivirals and with a synergistic effect when associated to antiviral agents. Ozanimod was approved by the FDA for the treatment of relapsing multiple sclerosis at the end of March 2020, and was recently (October 2020) approved by Health Canada for the same indication. The investigators believe that this immune modulator is at the top of the list of agents that should be trialed in order to mitigate the morbidity and mortality of COVID-19.

The primary objective is to substantiate the impact of ozanimod on key outcomes of COVID-19 patient progression, which will guide decision making around sample size and the choice of endpoints for future clinical trial.


Condition or disease Intervention/treatment Phase
COVID-19 Drug: Ozanimod Other: Standard of care Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial
Actual Study Start Date : September 16, 2020
Actual Primary Completion Date : March 14, 2022
Actual Study Completion Date : May 12, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ozanimod + standard of care
During hospitalization, the experiment treatment of Ozanimod will be given with the standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data.).
Drug: Ozanimod
The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.
Other Name: Zeposia (USA)

Other: Standard of care
During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).

Active Comparator: Standard of care
During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
Other: Standard of care
During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).




Primary Outcome Measures :
  1. Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
    Clinical improvement until hospital discharge


Secondary Outcome Measures :
  1. The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92% [ Time Frame: First 7 days of the trial ]
    Titrated every second with automated oxygen titration device (FreeO2)

  2. Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
  3. Rate of intubation [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
  4. Ventilator-free and oxygen-free days at day 28 [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
  5. Rate of ICU admission/length of stay/mortality [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
  6. Severity index measurement [ Time Frame: through whole duration of the hospitalization, an average of 14 days ]
    Sepsis-related organ failure assessment (SOFA), national early warning score (NEWS2), early warning score for oxygen therapy (EWS.O2), decrease of at least 2 points on the 6-point ordinal scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  • Confirmed COVID-19 (positive polymerase chain reaction (PCR) for COVID-19 from any specimen)
  • Patients older than 18 years old and younger than 85 years old.
  • BMI higher than 20 but lower than 40
  • Patients with hypoxemia related to viral pneumonia (COVID-19) requiring oxygen or nasal high flow therapy (to maintain SpO2 above 92%) without criteria for immediate intubation or need for other respiratory supports (CPAP, non-invasive ventilation).
  • Initiation of oxygen supplementation < 72 hours
  • eGFR (CKD EPI) > 30 ml/min/1.73m2
  • Serum troponin i < 80 ng/L
  • Heart rate ≥ 55 bpm if beta blockers or calcium channel blocker nondihydropyridine are used, and ≥ 60 bpm in the other patients

Exclusion criteria Medical conditions

  • Level of care B (unless patient agrees to intubation at study enrollment), C or D (patient admitted for palliative care; or physician is not committed to life-sustaining therapies)
  • No SpO2 signal available (only if FreeO2 apparatus is used)
  • Patient agitation (only if FreeO2 apparatus is used)
  • Severe untreated sleep apnea
  • History of or currently active primary or secondary immunodeficiency
  • Recent (within the last 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, class III/IV heart failure
  • Known presence of Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker
  • Child-Pugh score class C
  • Pregnancy, lactation, or a positive serum beta human chorionic gonadotropin measured during screening
  • Persistent hypotension.

Prior/concomitant therapy

  • Receipt of a live vaccine within 4 weeks prior to randomization
  • Receiving MAO inhibitor (tranylcypromine, selegiline or phenelzine)
  • Receiving pharmacological treatment for a form of multiple sclerosis
  • Use of long-term immunosuppressors (Ex. tacrolimus, cyclosporin, azathioprine, mycophenolate, sirolimus, methotrexate or chronic use of corticosteroid (> 7.5 mg per day more than 3 months)
  • Receiving Class Ia and class III anti-arrythmic drugs amiodarone, sotalol, flecainide, propafenone
  • Patients receiving or anticipated to receive hydroxychloroquine or azithromycin.

Prior/concurrent clinical study experience -Current enrolment in an interventional arm of a clinical trial with similar endpoints to the COZI trial

Other exclusions

-Patients or legal/authorized representatives who refuse to participate to the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04405102


Locations
Layout table for location information
Canada, Quebec
Hôpital de la Cité-de-la-Santé (CISSS de Laval)
Laval, Quebec, Canada, H7M 3L9
Hôpital Santa Cabrini Ospedale (CIUSSS EMTL)
Montréal, Quebec, Canada, H1T 1P7
Canada
Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval
Québec, Canada, G1V 4G5
Sponsors and Collaborators
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Celgene
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: François Lellouche, MD IUCPQ-UL
Study Chair: David Marsolais, PhD CRIUCPQ-UL
Study Chair: Nathalie Châteauvert, B. pharm CRIUCPQ-UL
Study Director: Pascale Blais-Lecours, PhD CRIUCPQ-UL
Layout table for additonal information
Responsible Party: François Lellouche, MD, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
ClinicalTrials.gov Identifier: NCT04405102    
Other Study ID Numbers: 2021-3474
First Posted: May 28, 2020    Key Record Dates
Last Update Posted: May 20, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by François Lellouche, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec:
S1P1 ligand
SARS-CoV-2
Oxygen requirement
WHO-adapted 6-points ordinal scale
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Ozanimod
Sphingosine 1 Phosphate Receptor Modulators
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs